In addition, over-expression of HelQ promotes resistance to treatments for ovarian cancers that are based on use of DNA crosslinkers (21,22), implicating HelQ levels in cells as potential factor to be overcome in hard-to-treat cancers. This evidence concerns the gene HELQ and ovarian carcinoma.